Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Primary Debulking Surgery for Stage III Epithelial Ovarian Cancer Has a Better Outcome Than Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery
Surgical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
,
Surgical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
,
Medical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
,
Department of Obstetrics and Gynecology, Al-Alzhar University, Assiut, Egypt
,
Medical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
1 Surgical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
2 Surgical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
3 Medical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
4 Department of Obstetrics and Gynecology, Al-Alzhar University, Assiut, Egypt
5 Medical Oncology Department, South Egypt Cancer Institute; Assiut University, Assiut, Egypt
Background: Ovarian cancer (OC) is the most lethal gynecologic malignancy. About 70% of ovarian cancer patients have advanced disease and often not totally resectable. Previous studies of neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) versus primary debulking surgery (PDS) give inconsistent results. The aim of this retrospective study is to evaluate the outcome of the neoadjuvant chemotherapy followed by IDS versus PDS followed by adjuvant chemotherapy for the International Federation of Gynecology and Obstetrics (FIGO) stage III epithelial ovarian cancer. Methods: This study was performed on eligible patients with ovarian cancer admitted in Surgical Oncology and Medical Oncology departments at South Egypt Cancer Institute-Assiut University in the period from January 2010 to December 2015. Patients were divided into two groups, the first group included those who have NACT and underwent IDS plus adjuvant chemotherapy, and the second group included those who underwent PDS followed by adjuvant chemotherapy. Results: This study included 380 cases. One hundred and fifty-four patients (40.53%) had IDS. The remaining two hundred and twenty-six patients (59.47%) underwent PDS. In this study, treatment modality was significant for both disease-free survival (DFS) and overall survival (OS). DFS was significantly reduced after IDS when compared to PDS (median DFS: 33.00 months vs. 45.00 months, respectively; p < 0.001). Also, OS was significantly reduced after IDS when compared to PDS. (Median OS: 43 months vs. 46 months, respectively; p = 0 .047). Moreover, this drop of the survivals mainly occurred in specific subgroups such as the elderly patients, patients with bad performance status, suboptimal cytoreduction, as well as high-grade tumors. Conclusion: This study showed that PDS resulted in a better disease-free survival and overall survival than IDS. Moreover, OS and DFS have significantly dropped in specific patients’ subgroups. Therefore, patients selection should be considered.
KeywordsPrimary Debunking SurgeryInterval Debunking SurgeryStage III Ovarian CancerNeoadjuvant Chemotherapy
Jemel, A., Tiwari, R.C., Murray, T., et al. (2004) Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8-29. https://doi.org/10.3322/canjclin.54.1.8
Harries, M. and Gore, M. (2002) Part I: Chemotherapy for Epithelial Ovarian Cancer Treatment at First Diagnosis. The Lancet Oncology, 3, 529-536. https://doi.org/10.1016/S1470-2045(02)00846-X
Griffiths, C.T., Parker, L.M. and Fuller, A.F. (1979) Role of Cytoreductive Surgical Treatment in the Management of Advanced Ovarian Cancer. Cancer Treatment Reviews, 63, 235-240.
Hoskins, W.J. (1993) Surgical Staging and Cytoreductive Surgery of Epithelial Ovarian Cancer. Cancer, 71, 1534-1540. https://doi.org/10.1002/cncr.2820710420
Hoskins, W.J., Bundy, B.N., Thigpen, J.T. and Omura, G.A. (1992) The Influence of Cytoreductive Surgery on Recurrence-Free Interval and Survival in Small-Volume Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology, 47, 159-166. https://doi.org/10.1016/0090-8258(92)90100-W
Chi, D.S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitao, M.M., Levine, D.A., Gardner, G.J., Abu-Rustum, N.R. and Barakat, R.R. (2012) An Analysis of Patients with Bulky Advanced Stage Ovarian, Tubal, and Peritoneal Carcinoma Treated with Primary Debulking Surgery (PDS) during an Identical Time Period as the Randomized EORTC-NCIC Trial of PDS vs Neoadjuvant Chemotherapy (NACT). Gynecologic Oncology, 124, 10-14. https://doi.org/10.1016/j.ygyno.2011.08.014
Vergote, I., De Wever, I., Tjalma, W., Van Gramberen, M., Decloedt, J. and van Dam, P. (1998) Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients. Gynecologic Oncology, 71, 431-436. https://doi.org/10.1006/gyno.1998.5213
Inciura, A., Simavicius, A., Juozaityte, E., Kurtinaitis, J., Nadisauskiene, R., Svedas, E. and Kajenas, S. (2006) Comparison of Adjuvant and Neoadjuvant Chemotherapy in the Management of Advanced Ovarian Cancer: A Retrospective Study of 574 Patients. BMC Cancer, 6, 153. https://doi.org/10.1186/1471-2407-6-153
Schwartz, P.E., Rutherford, T.J., Chambers, J.T., Kohorn, E.I. and Thiel, R.P. (1999) Neoadjuvant Chemotherapy for Advanced Ovarian Cancer Long-Term Survival. Gynecologic Oncology, 72, 93-99. https://doi.org/10.1006/gyno.1998.5236
Morice, P., Dubernard, G., Rey, A., Atallah, D., Pautier, P., Pomel, C., Lhomme, C., Duvillard, P. and Castaigne, D. (2003) Results of Interval Debulking Surgery Compared with Primary Debulking Surgery in Advanced Stage Ovarian Cancer. Journal of the American College of Surgeons, 197, 955-963. https://doi.org/10.1016/j.jamcollsurg.2003.06.004
Sehouli, J., Savvatis, K., Braicu, E.I., Schmidt, S.C., Lichtenegger, W. and Fotopoulou, C. (2010) Primary versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results from a Systematic Single-Center Analysis. International Journal of Gynecological Cancer, 20, 1331-1340.
Bristow, R.E. and Chi, D.S. (2006) Platinum-Based Neoadjuvant Chemotherapy and Interval Surgical Cytoreduction for Advanced Ovarian Cancer: A Meta-Analysis. Gynecologic Oncology, 103, 1070-1076. https://doi.org/10.1016/j.ygyno.2006.06.025
Coleridge, S.L., Bryant, A., Lyons, T.J., Goodall, R.J., Kehoe, S. and Morrison, J. (2019) Chemotherapy versus Surgery for Initial Treatment in Advanced Ovarian Epithelial Cancer. Cochrane Database of Systematic Reviews, CD005343. https://doi.org/10.1002/14651858.CD005343.pub4
Kobal, B., Noventa, M., Cvjeticanin, B., Barbic, M., Meglic, L., Herzog, M., et al. (2018) Primary Debulking Surgery versus Primary Neoadjuvant Chemotherapy for High Grade Advanced Stage Ovarian Cancer: Comparison of Survivals. Radiology and Oncology, 52, 307-319. https://doi.org/10.2478/raon-2018-0030
Yang, L., Zhang, B., Xing, G., Du, J., Yang, B., Yuan, Q., et al. (2017) Neoadjuvant Chemotherapy versus Primary Debulking Surgery in Advanced Epithelial Ovarian Cancer: A Meta-Analysis of Peri-Operative Outcome. PLoS ONE, 12, e0186725. https://doi.org/10.1371/journal.pone.0186725
Xiao, Y., Xie, S., Zhang, N., Wang, J., Lv, C., Guo, J., et al. (2018) Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis. Gynecologic and Obstetric Investigation, 83, 209-219. https://doi.org/10.1159/000485618
May, T., Comeau, R., Sun, P., Kotsopoulos, J., Narod, S.A., Rosen, B., et al. (2017) A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated with Primary Debulking Surgery versus Neoadjuvant Chemotherapy. International Journal of Gynecological Cancer, 27, 668-674. https://doi.org/10.1097/IGC.0000000000000946
Siesto, G., Cavina, R., Romano, F. and Vitobello, D. (2018) Primary Debulking Surgery versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-Matched Analysis. American Journal of Clinical Oncology, 41, 280-285.
Kayikcioglu, F., Kose, M.F., Boran, N., Caliskan, E. and Tulunay, G. (2001) Neoadjuvant Chemotherapy or Primary Surgery in Advanced Epithelial Ovarian Carcinoma. International Journal of Gynecological Cancer, 11, 466-470. https://doi.org/10.1046/j.1525-1438.2001.01064.x
Surwit, E., Childers, J., Atlas, I., Nour, M., Hatch, K., Hallum, A. and Alberts, D. (1996) Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 6, 356-361. https://doi.org/10.1046/j.1525-1438.1996.06050356.x
Chambers, J.T., Chambers, S.K., Voynick, I.M. and Schwartz, P.E. (1990) Neo-Adjuvant Chemotherapy in Stage X Ovarian Carcinoma. Gynecologic Oncology, 37, 327-331. https://doi.org/10.1016/0090-8258(90)90361-N
Schwartz, P.E., Chambers, J.T. and Makuch, R. (1994) Neoadjuvant Chemotherapy for Advanced Ovarian Cancer. Gynecologic Oncology, 53, 33-37. https://doi.org/10.1006/gyno.1994.1083
Hoskins, W.J. (1993) Surgical Staging and Cytoreductive Surgery of Epithelial Ovarian Cancer. Cancer, 71, 1534-1540. https://doi.org/10.1002/cncr.2820710420
Jacob, J.H., Gershenson, D.M., Morris, M., Copeland, L.J., Burke, T.W. and Wharton, J.T. (1991) Neoadjuvant Chemotherapy and Interval Debulking for Advanced Epithelial Ovarian Cancer. Gynecologic Oncology, 42, 146-150. https://doi.org/10.1016/0090-8258(91)90335-3
Gao, Y., Li, Y., Zhang, J., Han, L.H., Zhang, K. and Guo, H. (2019) Evaluating the Benefits of Chunyu Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer: A Retrospective Study. Journal of Ovarian Research, 12, 85. https://doi.org/10.1186/s13048-019-0562-9
Manning-Geist, B.L., Hicks-Courant, K., Gockley, A.A., Clark, R.M., Del Carmen, M., Growdon, W.B., et al. (2018) Moving beyond “Complete Surgical Resection” and “Optimal”: Is Low-Volume Residual Disease Another Option for Primary Debulking Surgery? Gynecologic Oncology, 150, 233-238. https://doi.org/10.1016/j.ygyno.2018.06.015